

Supplemental Table 1. All Factors Examined for Prediction of Remission of Chronic Anterior Uveitis (Hazard Ratios Less than 1 are Unfavorable, Indicating a Lower Incidence of Remission).†

		Remission			Crude		Adjusted*	
		Total	No	Yes	Hazard Ratio (95% CI)	p	Hazard Ratio (95% CI)	p
Age at presentation	<40	1384 (50%)	1106 (80%)	278 (20%)	Ref	<0.001	Ref	0.03
	40+	1411 (50%)	1027 (73%)	384 (27%)	1.77 (1.46, 2.16)		1.29 (1.02, 1.63)	
Sex	Male	967 (35%)	730 (75%)	237 (25%)	Ref	0.96	Ref	0.42
	Female	1828 (65%)	1403 (77%)	425 (23%)	1.00 (0.82, 1.23)		1.09 (0.88, 1.36)	
Race category	White	1682 (60%)	1250 (74%)	432 (26%)	Ref	0.82	Ref	0.81
	Black	449 (16%)	355 (79%)	94 (21%)	0.90 (0.67, 1.19)		0.89 (0.66, 1.19)	
	Hispanic	120 (4%)	96 (80%)	24 (20%)	0.85 (0.50, 1.42)		1.15 (0.67, 1.98)	
	Other	544 (19%)	432 (79%)	112 (21%)	0.95 (0.72, 1.24)		0.98 (0.74, 1.31)	
Smoking	Never	1999 (72%)	1543 (77%)	456 (23%)	Ref	0.08	Ref	0.47
	Past	309 (11%)	217 (70%)	92 (30%)	1.47 (1.10, 1.97)		1.08 (0.78, 1.50)	
	Current	313 (11%)	241 (77%)	72 (23%)	1.08 (0.80, 1.47)		0.81 (0.58, 1.14)	
	Unknown	174 (6%)	132 (76%)	42 (24%)	1.08 (0.72, 1.61)		0.82 (0.51, 1.31)	
Bilateral	No	379 (14%)	283 (75%)	96 (25%)	Ref	0.008	Ref	0.02
	Yes	2416 (86%)	1850 (77%)	566 (23%)	0.73 (0.58, 0.92)		0.75 (0.59, 0.96)	
Duration of uveitis prior to presentation	<6 Months	834 (30%)	593 (71%)	241 (29%)	Ref	<0.001	Ref	0.02
	6 Months to <2 Years	620 (22%)	464 (75%)	156 (25%)	0.81 (0.63, 1.05)		0.78 (0.60, 1.03)	
	2 to <5 Years	512 (18%)	414 (81%)	98 (19%)	0.58 (0.43, 0.78)		0.61 (0.44, 0.83)	
	5+ Years	829 (30%)	662 (80%)	167 (20%)	0.63 (0.48, 0.81)		0.76 (0.58, 1.01)	
Prior cataract surgery	No	2231 (80%)	1698 (76%)	533 (24%)	Ref	0.03	Ref	0.002
	Yes	564 (20%)	435 (77%)	129 (23%)	0.80 (0.65, 0.97)		0.70 (0.56, 0.88)	

		Remission			Crude		Adjusted*	
		Total	No	Yes	Hazard Ratio (95% CI)	p	Hazard Ratio (95% CI)	p
Pars Plana Vitrectomy (not for Retinal Detachment)	No	2721 (97%)	2068 (76%)	653 (24%)	Ref	0.004	Ref	0.16
	Yes	74 (3%)	65 (88%)	9 (12%)	0.52 (0.34, 0.82)		0.72 (0.45, 1.15)	
Any glaucoma surgery	No	2627 (94%)	1995 (76%)	632 (24%)	Ref	0.001	Ref	0.01
	Yes	168 (6%)	138 (82%)	30 (18%)	0.59 (0.43, 0.81)		0.63 (0.45, 0.90)	
Inflammatory activity at baseline	Inactive	1138 (43%)	869 (76%)	269 (24%)	Ref	0.09	Ref	0.98
	Slightly active	381 (14%)	274 (72%)	107 (28%)	1.22 (0.92, 1.61)		0.96 (0.68, 1.38)	
	Active	1156 (43%)	907 (78%)	249 (22%)	0.89 (0.73, 1.10)		0.99 (0.72, 1.37)	
Anterior chamber cells at baseline	Quiet	1153 (43%)	884 (77%)	269 (23%)	Ref	<0.001	Ref	<0.001
	0.5+	530 (20%)	369 (70%)	161 (30%)	1.46 (1.17, 1.83)		1.48 (1.17, 1.87)	
	1+	472 (18%)	377 (80%)	95 (20%)	0.89 (0.68, 1.16)		0.88 (0.66, 1.17)	
	≥2+	526 (20%)	421 (80%)	105 (20%)	0.79 (0.61, 1.02)		0.87 (0.66, 1.15)	
Vitreous cells at baseline	Quiet	1867 (76%)	1442 (77%)	425 (23%)	Ref	0.12	Ref	0.17
	0.5+	210 (9%)	146 (70%)	64 (30%)	1.30 (0.97, 1.75)		1.14 (0.80, 1.63)	
	1+	232 (9%)	184 (79%)	48 (21%)	0.87 (0.63, 1.20)		0.73 (0.52, 1.04)	
	≥2+	143 (6%)	111 (78%)	32 (22%)	0.77 (0.50, 1.18)		0.75 (0.46, 1.21)	
Keratic precipitates	No	2079 (83%)	1580 (76%)	499 (24%)	Ref	<0.001	Ref	<0.001
	Yes	430 (17%)	334 (78%)	96 (22%)	0.37 (0.22, 0.61)		0.36 (0.21, 0.60)	
Band Keratopathy	No	2276 (91%)	1709 (75%)	567 (25%)	Ref	<0.001	Ref	0.14
	Yes	231 (9%)	202 (87%)	29 (13%)	0.41 (0.29, 0.58)		0.75 (0.51, 1.10)	

		Remission			Crude		Adjusted*	
		Total	No	Yes	Hazard Ratio (95% CI)	p	Hazard Ratio (95% CI)	p
Synechia	Neither	1940 (72%)	1459 (75%)	481 (25%)	Ref	<0.001	Ref	0.008
	Peripheral Synechia Only	61 (2%)	43 (70%)	18 (30%)	0.74 (0.42, 1.29)		0.69 (0.36, 1.32)	
	Posterior Synechia Only	604 (23%)	488 (81%)	116 (19%)	0.67 (0.55, 0.83)		0.72 (0.58, 0.90)	
	Posterior and Peripheral Synechia	79 (3%)	66 (84%)	13 (16%)	0.56 (0.38, 0.84)		0.62 (0.41, 0.93)	
Macular Edema	No	1967 (89%)	1512 (77%)	455 (23%)	Ref	0.63	Ref	0.50
	Yes	232 (11%)	166 (72%)	66 (28%)	0.91 (0.62, 1.33)		1.14 (0.78, 1.67)	
Sarcoidosis	No	2548 (91%)	1949 (76%)	599 (24%)	Ref	0.99	Ref	0.20
	Yes	247 (9%)	184 (74%)	63 (26%)	1.00 (0.72, 1.40)		0.79 (0.55, 1.13)	
Juvenile Idiopathic Arthritis	No	2192 (78%)	1602 (73%)	590 (27%)	Ref	<0.001	Ref	<0.001
	Yes	603 (22%)	531 (88%)	72 (12%)	0.34 (0.25, 0.47)		0.37 (0.26, 0.53)	
Spondyloarthropathy	No	2525 (90%)	1899 (75%)	626 (25%)	Ref	<0.001	Ref	<0.001
	Yes	270 (10%)	234 (87%)	36 (13%)	0.41 (0.27, 0.62)		0.35 (0.23, 0.54)	
HLAB27	No	2401 (86%)	1843 (77%)	558 (23%)	Ref	0.37	Ref	0.10
	Yes	394 (14%)	290 (74%)	104 (26%)	0.89 (0.69, 1.15)		1.27 (0.96, 1.68)	
Behçet Disease	No	2774 (99%)	2118 (76%)	656 (24%)	Ref	0.36	Ref	0.12
	Yes	21 (1%)	15 (71%)	6 (29%)	0.72 (0.35, 1.47)		0.46 (0.17, 1.23)	
Systemic Lupus	No	2772 (99%)	2111 (76%)	661 (24%)	Ref	0.06	Ref	0.055
	Yes	23 (1%)	22 (96%)	1 (4%)	0.16 (0.02, 1.04)		0.18 (0.03, 1.03)	
Diabetes	No	2566 (92%)	1973 (77%)	593 (23%)	Ref	0.007	Ref	0.37
	Yes	229 (8%)	160 (70%)	69 (30%)	1.56 (1.13, 2.16)		1.18 (0.82, 1.69)	

		Remission			Crude		Adjusted*	
		Total	No	Yes	Hazard Ratio (95% CI)	p	Hazard Ratio (95% CI)	p
Hypertension	No	2085 (75%)	1632 (78%)	453 (22%)	Ref	0.003	Ref	0.78
	Yes	710 (25%)	501 (71%)	209 (29%)	1.38 (1.11, 1.70)		0.96 (0.74, 1.25)	
Hyperlipidemia	No	2506 (90%)	1931 (77%)	575 (23%)	Ref	0.007	Ref	0.42
	Yes	289 (10%)	202 (70%)	87 (30%)	1.46 (1.11, 1.92)		1.13 (0.84, 1.52)	
Statins ≥90 days	No	2576 (92%)	1972 (77%)	604 (23%)	Ref	0.003	Ref	0.40
	Yes	219 (8%)	161 (74%)	58 (26%)	1.68 (1.20, 2.35)		1.17 (0.81, 1.69)	
ACE Inhibitors ≥90 days	No	2628 (94%)	2010 (76%)	618 (24%)	Ref	0.006	Ref	0.32
	Yes	167 (6%)	123 (74%)	44 (26%)	1.67 (1.16, 2.42)		1.24 (0.81, 1.87)	
Aspirin ≥90 days	No	2660 (95%)	2033 (76%)	627 (24%)	Ref	0.01	Ref	0.49
	Yes	135 (5%)	100 (74%)	35 (26%)	1.78 (1.14, 2.78)		1.18 (0.73, 1.90)	

† Includes eyes of patients who did not return for follow-up after 90 days, but had 1 or more follow-up visits before 90 days and had remained inactive without receiving suppressive medications at all of those visits, as being in remission.

* Adjusted for age at presentation, bilateral, duration of uveitis prior to presentation, prior cataract surgery, any glaucoma surgery, anterior chamber cells at baseline, keratic precipitates, synechia, juvenile idiopathic arthritis, spondyloarthropathy